Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
An exploratory open-label study of PPTH patients to study the efficacy and tolerability of
erenumab in the prophylactic treatment of persistent headache attributed to mild traumatic
injury to the head. Approximately 100 subjects will be included to erenumab 140 mg. Patients
who have participated in study with prior provocation (Ethics Committee of the Capital Region
of Denmark (H-1801147 and H-18050498) and who have consented to be contacted will primarily
be included. The study will begin February 2019 and is expected to last one year. Patients
responding to advertisement (see add) will be contacted by phone.